Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)
Non-Hodgkin's Lymphoma
About this trial
This is an interventional treatment trial for Non-Hodgkin's Lymphoma focused on measuring Non-Hodgkin's lymphoma, intermediate-grade lymphoma, high-grade lymphoma, CHOP protocol, granulocyte-colony stimulating factor
Eligibility Criteria
Inclusion Criteria: Intermediate- or high-grade non-Hodgkin's lymphoma, excluding cutaneous t-cell lymphoma (CTCL), adult T-cell leukemia-lymphoma (ATL) and T-cell lymphoblastic lymphoma (T-LbL) (Working Formulation) Ann Arbor stage: II, III, IV No prior chemotherapy or radiotherapy Age: 15 to 69 Performance status (PS): 0, 1, 2 WBC >= 3,000 /mm3, ANC >= 1,200 /mm3, Platelet >= 75,000 /mm3 GOT/GPT <= 5 x Normal Upper Limit, T-Bil <= 2.0 mg/dL Creatinine <= 2.0 mg/dL Normal ECG, Ejection Fraction >= 50% PaO2 >= 65 mmHg Written informed consent Exclusion Criteria: Uncontrollable diabetes mellitus Severe complication (infection, heart failure, renal failure, liver failure, etc) Anamnesis of heart disease Acute or chronic hepatitis, liver cirrhosis and portal hypertension Synchronous or metachronous malignancy Severe pulmonary dysfunction Central nervous system (CNS) invasion HIV positive Hepatitis B surface antigen (HBs-Ag) positive Hepatitis C virus antibody (HCV-Ab) positive
Sites / Locations
- Tokai University